Company Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 19/07/2024 BST 5-day change 1st Jan Change
6.11 USD +0.66% Intraday chart for Vanda Pharmaceuticals Inc. +3.21% +44.79%

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Number of employees: 203

Sales per Business

USD in Million2022Weight2023Weight Delta
Therapies
100.0 %
254 100.0 % 193 100.0 % -24.27%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
254 100.0 % 193 100.0 % -24.27%

Managers

Managers TitleAgeSince
Chief Executive Officer 64 31/10/02
Director of Finance/CFO 40 30/11/12
Human Resources Officer - 31/07/19
Sales & Marketing 58 20/08/19
General Counsel 48 12/08/18
Corporate Officer/Principal 55 31/05/03
Corporate Officer/Principal 73 31/07/05

Members of the board

Members of the board TitleAgeSince
Director/Board Member 82 30/11/05
Chief Executive Officer 64 31/10/02
Director/Board Member 72 13/02/20
Director/Board Member 52 27/10/19
Director/Board Member 44 23/04/19
Director/Board Member 73 14/03/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 58,198,273 56,353,833 ( 96.83 %) 0 96.83 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
12.71 %
7,399,255 12.71 % 42 M $
Renaissance Technologies LLC
7.347 %
4,275,625 7.347 % 24 M $
Vanguard Fiduciary Trust Co.
5.835 %
3,395,583 5.835 % 19 M $
Acadian Asset Management LLC
4.073 %
2,370,335 4.073 % 13 M $
1,871,730 3.216 % 11 M $
D.E. Shaw & Co., Inc.
3.098 %
1,802,842 3.098 % 10 M $
Tang Capital Management LLC
3.010 %
1,751,654 3.010 % 10 M $
DFA Australia Ltd.
2.799 %
1,628,901 2.799 % 9 M $
Morgan Stanley Investment Management, Inc.
2.592 %
1,508,648 2.592 % 9 M $
Jacobs Levy Equity Management, Inc.
2.439 %
1,419,560 2.439 % 8 M $

Company contact information

Vanda Pharmaceuticals, Inc.

2200 Pennsylvania Avenue NW Suite 300E

20037, Washington

+202 734 3400

http://www.vandapharma.com
address Vanda Pharmaceuticals Inc.(VNDA)
  1. Stock Market
  2. Equities
  3. VNDA Stock
  4. Company Vanda Pharmaceuticals Inc.